| FDA regulatory decisions for Roche's Gazyva in Immunoglobulin Nephropathy Syndrome (INS) and Membranous Nephropathy (MN), and FDA regulatory approval for Johnson & Johnson's IMAAVY in warm autoimmune hemolytic anemia (wAIHA). | September 2026 - November 2026 | 2026-09-01 | 2026-11-30 | These approvals represent significant market expansion and revenue diversification for two major established pharma companies, directly impacting the theme's bullish outlook on robust pipelines and high-margin opportunities. | Theme | theme_composer | RHHBY, JNJ | 2 | 0.0218 | 1.18 | 1.0 | Regulatory/Policy | 1.35 | 3.473 | 2026-09-08 | False | 2 | 0.4089 | 65.1427 | | Theme composer | | |
| Initiation of Roche's Phase III trials for petrelintide monotherapy, CT-996, and the Synergy study (enicepatide + petrelintide combination) in obesity, alongside key data readouts for Johnson & Johnson's Innovative Medicine pipeline assets including TECVAYLI combinations, INLEXZO, ICOTYDE in psoriatic arthritis, and CAPLYTA in bipolar mania. | H2 2026 | 2026-07-01 | 2026-12-31 | Roche's entry into the high-growth obesity market with multiple differentiated assets and JNJ's pipeline advancements are crucial for sustaining long-term growth and offsetting patent expirations, reinforcing the theme's bullish thesis on leveraging cutting-edge research and robust pipelines. | Theme | theme_composer | RHHBY, JNJ | 2 | 0.0218 | 1.18 | 0.92 | Regulatory/Policy | 1.35 | 3.1951 | 2026-09-08 | False | 1 | 0.4089 | 59.9313 | | Theme composer | | |
| European regulatory approval for Foundayo (chronic weight management and type 2 diabetes) following a positive CHMP opinion. | by year end | 2026-10-01 | 2026-12-31 | This approval is crucial for the anticipated global rollout of Foundayo in major markets in 2027, significantly expanding its international revenue potential. | Ticker | | | | | | | | | | | | | | | earnings_transcript | LLY (ticker) | LLY_10dadbeb | 2026-10-29 |
| Readout of Foundayo Phase 3 trial in obstructive sleep apnea. | later this year | 2026-10-01 | 2026-12-31 | Positive results from this trial could lead to a new, high-value indication for Foundayo, further expanding its utility and market potential beyond its current metabolic indications. | Ticker | | | | | | | | | | | | | | | earnings_transcript | LLY (ticker) | LLY_48d9403d | 2026-08-05 |
| U.S. regulatory action (approval/decision) for Foundayo in type 2 diabetes. | later this year | 2026-10-01 | 2026-12-31 | This regulatory decision would significantly expand Foundayo's addressable market in the U.S. to include type 2 diabetes, a large and established indication, driving substantial revenue growth. | Ticker | | | | | | | | | | | | | | | earnings_transcript | LLY (ticker) | LLY_696cb569 | 2026-08-05 |
| Launch of Orforglipron in a few international markets (e.g., UAE). | a few markets late in 2026 | 2026-10-01 | 2026-12-31 | This marks the beginning of the international rollout for oral Orforglipron, contributing to global revenue growth and market penetration. | Ticker | | | | | | | | | | | | | | | earnings_transcript | LLY (ticker) | LLY_cf82d1b5 | 2026-02-04 |
| US regulatory approval decision for RINVOQ for the treatment of vitiligo. | later this year | 2026-10-01 | 2026-12-31 | This approval would mark RINVOQ as the first systemic treatment for vitiligo, significantly expanding its market potential and contributing to the anticipated combined peak sales of $2 billion for vitiligo and alopecia areata indications. | Ticker | | | | | | | | | | | | | | | earnings_transcript | ABBV (ticker) | ABBV_c5da1469 | 2026-07-31 |
| Resolution of ongoing discussions with the FDA regarding TABNIO's (avacopan) following a voluntary withdrawal request related to primary endpoint result readjudication. | We will update you on those discussions as necessary. | 2026-04-24 | 2026-12-31 | The outcome will determine the future commercial viability of TABNIO's, impacting Amgen's rare disease portfolio and potentially leading to a re-evaluation of the product's sales trajectory. | Ticker | | | | | | | | | | | | | | | earnings_transcript | AMGN (ticker) | AMGN_fe4d51bf | 2026-02-03 |
| Potential approval of povorcitinib for the treatment of moderate to severe hidradenitis suppurativa (HS) in Europe. | late 2026 | 2026-10-01 | 2026-12-31 | This would represent a new regulatory approval for povorcitinib, expanding its indications and contributing to the growth of Incyte's dermatology franchise in international markets. | Ticker | | | | | | | | | | | | | | | earnings_transcript | INCY (ticker) | INCY_e44c3728 | 2026-07-28 |
| Second readout from the ATLAS-UC trial for tulisokibart in moderately to severely active ulcerative colitis. | second half of 2026 | 2026-09-01 | 2026-12-31 | This readout, combined with the earlier induction study, will form the basis of a regulatory filing, reinforcing confidence in the program's potential and expanding Merck's immunology portfolio. | Ticker | | | | | | | | | | | | | | | earnings_transcript | MRK (ticker) | MRK_bcd577c2 | 2026-08-04 |
| FDA regulatory decision for CagriSema in the U.S. for obesity. | at the end of 2026 | 2026-10-01 | 2026-12-31 | Approval would introduce a new, potentially highly effective obesity treatment, strengthening Novo Nordisk's pipeline and competitive position. | Ticker | | | | | | | | | | | | | | | earnings_transcript | NVO (ticker) | NVO_71e5b33d | 2026-05-06 |
| First readout of the MEVPRO-1 Phase III study for mevrometostat in post-abiraterone metastatic hormone-resistant prostate cancer. | fourth quarter | 2026-10-01 | 2026-12-31 | This pivotal study readout could establish mevrometostat as a breakthrough therapy, delaying resistance to XTANDI and representing a 100% global commercial opportunity for Pfizer. | Ticker | | | | | | | | | | | | | | | earnings_transcript | PFE (ticker) | PFE_fe771000 | 2026-08-04 |
| Presentation of the full data set from the TRANQUILLO 1 and 2 studies for Litfulo in nonsegmental vitiligo. | later this year at a conference | 2026-09-01 | 2026-12-31 | The full data presentation will provide comprehensive insights into Litfulo's clinically meaningful and statistical efficacy, reinforcing its potential in the vitiligo market. | Ticker | | | | | | | | | | | | | | | earnings_transcript | PFE (ticker) | PFE_0a01f9d3 | 2026-08-04 |
| Start of a pivotal trial investigating NURTEC's use as a treatment for chronic migraine. | this year | 2026-09-01 | 2026-12-31 | This pivotal trial initiation aims to expand NURTEC's label, further strengthening Pfizer's leadership in providing treatment options for migraine patients. | Ticker | | | | | | | | | | | | | | | earnings_transcript | PFE (ticker) | PFE_a3b83d3f | 2026-08-04 |
| Release of the clinical trial design for the adjuvant study of atirmociclib in ER-positive breast cancer. | later this year | 2026-09-01 | 2026-12-31 | This milestone is crucial for advancing atirmociclib, which is believed to be highly differentiated in the early adjuvant setting due to its tolerability profile, representing a significant opportunity. | Ticker | | | | | | | | | | | | | | | earnings_transcript | PFE (ticker) | PFE_a1fcc382 | 2026-08-04 |
| FDA decision on the New Drug Application (NDA) for cemdisiran, an siRNA targeting C5, in generalized myasthenia gravis (gMG). | November of this year | 2026-11-01 | 2026-11-30 | Potential approval would introduce a highly differentiated treatment option for gMG patients with a convenient quarterly subcutaneous dosing profile, expanding Regeneron's rare disease portfolio. | Ticker | | | | | | | | | | | | | | | earnings_transcript | REGN (ticker) | REGN_0f639ad7 | 2026-07-30 |
| FDA approval of the EYLEA HD prefilled syringe. | before the end of the year | 2026-10-01 | 2026-12-31 | This product enhancement is expected to drive even further adoption of EYLEA HD, strengthening its competitive position and contributing to sales growth. | Ticker | | | | | | | | | | | | | | | earnings_transcript | REGN (ticker) | REGN_76369989 | 2026-07-30 |
| Initiation of multiple Phase III studies for olatorepatide in patients with obesity and in patients with obesity and type 2 diabetes. | later this year | 2026-10-01 | 2026-12-31 | Marks significant progress in Regeneron's obesity portfolio, positioning the company to enter a high-growth market with a potentially differentiated dual GLP-GIP receptor agonist. | Ticker | | | | | | | | | | | | | | | earnings_transcript | REGN (ticker) | REGN_07f81147 | 2026-07-30 |
| U.S. FDA PDUFA date for Ladera in adjuvant ER-positive HER2-negative breast cancer. | November 30 | 2026-11-30 | 2026-11-30 | A positive FDA decision would enable the launch of Ladera, expanding Roche's oncology portfolio and addressing a significant unmet need in breast cancer treatment. | Ticker | | | | | | | | | | | | | | | earnings_transcript | RHHBY (ticker) | RHHBY_547ab592 | 2026-07-23 |
| FDA PDUFA date for Pove in IgAN. | November 30 PDUFA date | 2026-11-30 | 2026-11-30 | This is a pivotal regulatory decision for a potential best-in-class therapy, establishing a new multibillion-dollar renal franchise for Vertex. | Ticker | | | | | | | | | | | | | | | earnings_transcript | VRTX (ticker) | VRTX_c280265c | 2026-08-03 |
| Lilly Innovation Day. | December 7th | 2026-12-07 | 2026-12-07 | This event is expected to provide more detailed insights into Lilly's pipeline, potentially revealing new material information about future growth drivers and strategic priorities. | Ticker | | | | | | | | | | | | | | | earnings_transcript | LLY (ticker) | LLY_a24ab55b | 2026-10-29 |
| U.S. FDA PDUFA date for Avera. | December 18 | 2026-12-18 | 2026-12-18 | A positive FDA decision for Avera would further strengthen Roche's breast cancer franchise, offering another treatment option and contributing to future revenue. | Ticker | | | | | | | | | | | | | | | earnings_transcript | RHHBY (ticker) | RHHBY_3ff530ea | 2026-07-23 |
| U.S. regulatory submission (BLA pathway) for retatrutide. | Q1 2027 | 2027-01-01 | 2027-03-31 | This submission is a critical step towards bringing the highly efficacious triple agonist, retatrutide, to market, potentially solidifying Lilly's leadership in cardiometabolic health with a drug demonstrating unprecedented weight loss. | Ticker | | | | | | | | | | | | | | | earnings_transcript | LLY (ticker) | LLY_a075099b | 2026-10-29 |